Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Short term Debt (2020 - 2026)

Alx Oncology Holdings' Short term Debt history spans 4 years, with the latest figure at $830000.0 for Q1 2023.

  • On a quarterly basis, Short term Debt changed N/A to $830000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $830000.0, a N/A change, with the full-year FY2022 number at $1.6 million, up 1.23% from a year prior.
  • Short term Debt hit $830000.0 in Q1 2023 for Alx Oncology Holdings, down from $1.6 million in the prior quarter.
  • Over the last five years, Short term Debt for ALXO hit a ceiling of $2.8 million in Q3 2022 and a floor of $830000.0 in Q1 2023.
  • Historically, Short term Debt has averaged $2.0 million across 4 years, with a median of $1.7 million in 2020.
  • The widest YoY moves for Short term Debt: up 1.23% in 2022, down 1.23% in 2022.
  • Tracing ALXO's Short term Debt over 4 years: stood at $2.6 million in 2020, then tumbled by 36.6% to $1.6 million in 2021, then increased by 1.23% to $1.6 million in 2022, then tumbled by 49.7% to $830000.0 in 2023.
  • Business Quant data shows Short term Debt for ALXO at $830000.0 in Q1 2023, $1.6 million in Q4 2022, and $2.8 million in Q3 2022.